Improving coordination of lung cancer care at a tertiary healthcare center in Saudi Arabia

Article Figures & Data

Table 1

- Patient characteristics (N=60).

Characteristics	n (%)
Gender
Male	41 (68.3)
Female	19 (31.7)
Histology
Adenocarcinoma	38 (63.3)
Squamous cell carcinoma	14 (23.3)
Non-small cell lung cancer and poorly differentiated carcinoma	5 (8.4)
Adenosquamous and neuroendocrine	3 (5.0)
Stage
I	2 (3.3)
II	7 (11.7)
III	6 (10.0)
IV	42 (70.0)
Missing	3 (5.0)
EGFR status for stage IV and non-squamous NSCLC (n=30)
Mutant	7 (23.3)
Wild-type	23 (76.7)
ALK for the cases who are stage IV and non-squamous NSCLC and wild EGFR (n=19)
Mutant	2 (10.5)
Wild-type	17 (89.5)
ROS1 for the cases who are stage IV and non-squamous NSCLC and wild EGFR and ALK (n=15)
Mutant	1 (6.7)
Wild-type	14 (93.3)
Survival status
Dead	30 (50.0)
Alive	24 (40.0)
Lost to follow up	6 (10.0)

NSCLC: non-small cell lung carcinoma, ALK: anaplastic lymphoma kinase, EGFR: epidermal growth factor receptor, ROS1: c-ros oncogene 1

Table 2

- Adherence to molecular testing recommendations.

Molecular testing	n (%)
EGFR
The candidates for this test are stage IV and non-squamous NSCLC (n=30)	30 (100)
ALK
For the cases who are stage IV and non-squamous NSCLC and wild EGFR (n=23)	19 (82.6)
ROS1
For the cases who are stage IV and non-squamous NSCLC and wild EGFR and ALK (n=21)	15 (71.4)
PD-L1
For stage IV (n=42)	25 (59.5)

ALK: anaplastic lymphoma kinase, EGFR: epidermal growth factor receptor, ROS1: c-ros oncogene 1, PD-L1: programmed death ligand 1

Table 3

- Tumor board recommendations for the 40 cases which presented for 65 times (N=65).

Tumor board recommendations	n (%)
Active treatment per type
Surgery	9 (13.8)
Chemotherapy	18 (27.7)
Radiation	12 (18.5)
Palliative care	0 (0.0)
Overall active treatment
For the whole sample	31 (47.7)
Recommendation done	22 (71)
Further investigation
For the whole sample	20 (30.8)
Recommendation done	14 (70.0)
More imaging is needed
Magnetic resonance imaging	4 (6.2)
Computerized tomography scan	11 (16.9)
Positron emission tomography scan	10 (15.4)
Bone scan	1 (1.5)
Overall, the above imaging were requested for 20 case presentation	20 (30.8)
Recommendations done	20 (100)
Observation only
For the whole sample	1 (1.53)
Recommendation done	1 (100)
New findings
New findings in pathology	3 (7.5)
New findings in radiology	7 (17.5)
New findings in staging	5 (12.5)
Overall new findings in tumor board (unique cases)	11 (27.5)